Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Maintains Overweight on Abbott Laboratories, Lowers Price Target to $126

Morgan Stanley analyst Cecilia Furlong maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $132 to $126.
byBenzinga Newsdesk
October 11, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Morgan Stanley analyst Cecilia Furlong maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $132 to $126.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts